ArticleJapanese journal of ophthalmology2026
2024 survey of the frequency of fixed-combination eye drop use by patients with glaucoma at multiple private practices in Japan.
Article in Japanese journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the current (2024) use of fixed-combination eye drops in Japanese patients with glaucoma. STUDY
designCross-sectional survey.
methodsThe survey included 6323 outpatients (6323 eyes) with glaucoma or ocular hypertension at 82 private practices from March 10 to 16, 2024. The use of fixed-combination eye drops, including prostaglandin F (FP) receptor agonist/β-blocker (FP/β), carbonic anhydrase inhibitor/β-blocker (CAI/β), α2-adrenergic agonist/β-blocker (α2/β), α2-adrenergic agonist/carbonic anhydrase inhibitor (α2/CAI), and α2-adrenergic agonist/Rho-associated protein kinase (α2/ROCK), was analyzed, stratified by the number of medications used. The results were compared with those of a 2020 survey via χ
resultsFP/β, CAI/β, α2/β, α2/CAI, and α2/ROCK were used by respectively 56.4%, 8.0%, 2.2%, 2.9%, and 0.6% of 2-medication users; 42.5%, 30.2%, 3.2%, 11.2%, and 4.1% of 3-medication users; and 56.6%, 32.1%, 1.7%, 45.5%, and 14.4% of ≥4-medication users. FP/β were the most commonly used in all groups. Compared with the previous survey, the use of FP/β increased significantly in all groups, while that of CAI/β decreased significantly. Among four-medication users, 228 patients (44.4%) used two types of fixed-combination eye drops. In this group, FP/β + α2/CAI (186 cases) was the most common. Among five-medication users, 186 patients (69.9%) used two types of fixed-combination eye drops. In this group, FP/β + α2/CAI + one additional drug (131 cases) was the most common.
conclusionFixed-combination eye drops were used in >70% of patients using 2 medications and >90% of patients using ≥3 medications. Over time, the use of FP/β increased, while the use of CAI/β decreased.
Indexed as
Identifiers
42274971What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.